← All Drugs

Midazolam

Versed

Benzodiazepine Anxiolytic/Sedative (BZD)Schedule IVGeneric availableTDM data

Midazolam is a short-acting benzodiazepine that potentiates GABA-A receptor-mediated inhibition in the CNS via positive allosteric modulation. Ultra-short acting with terminal half-life of 1-4 hours (typically 1.5-2.5 hours), making it ideal for acute sedation, procedural sedation, and anesthesia induction. Has active metabolites (1-hydroxymidazolam and 4-hydroxymidazolam) which may contribute to prolonged CNS effects. Available in multiple routes (IV, IM, intranasal, oral), providing flexibility for acute agitation management.

Compare Midazolam

FDA-Approved Indications

  • Pre-operative sedation/anxiolysis/amnesia (IV, IM, intranasal)
  • Conscious sedation for diagnostic and therapeutic procedures (IV, IM, intranasal)
  • Acute agitation management (IM preferred)
  • Induction of general anesthesia (IV)

Common Off-Label Uses

  • Acute psychomotor agitation (IM — emergency departments)
  • Status epilepticus (intranasal Nayzilam)
  • Palliative sedation

What Sets This Drug Apart

  • Ultra-short acting (t1/2 1-4 hours) with multiple routes (IV, IM, intranasal) — ideal for acute situations
  • Approved for acute agitation management (IM) including psychotic agitation, depression, bipolar mania — rare benzo with acute behavioral indication
  • Active metabolites (1-hydroxy and 4-hydroxymidazolam) contribute to CNS effects; may accumulate with repeated dosing
  • REQUIRES resuscitation equipment and trained personnel due to respiratory depression/arrest risk — cannot be used without adequate monitoring
  • Significant respiratory depression risk especially with opioid co-administration and rapid IV infusion — restricts safe use populations
  • High abuse potential and physical dependence risk, particularly with prolonged use in hospital/ICU settings
Boxed Warning
Respiratory depression and respiratory arrest, particularly with IV use, opioid co-administration, and high doses
Boxed Warning
Profound sedation and CNS depression
Boxed Warning
Death reported with inadequate resuscitation equipment or experienced personnel not available
Boxed Warning
Abuse and dependence potential